Search results for "derived"

showing 10 items of 452 documents

Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation.

2006

Three commercial systems for whole blood separation were compared to obtain the buffy coat composed of platelet-rich plasma (BC-PRP) and leucocytes . These samples of the buffy coat were used to make a platelet gel (PG), which was used to measure platelet growth factor (PGF) release, to perform a white blood cell (WBC) count and to measure myeloperoxidase (MPO) release from WBCs. Aliquots of whole blood obtained from ten volunteers were distributed either to a blood cell separator (The Electa Cell-Separator (TM), E-CS) or to a tabletop centrifuge (Gravitational Platelet Sequestration System (TM), GPS) to prepare the BC-PRP. The third system combines the BC-PRP production by E-CS with a micr…

AdultBlood PlateletsBuffy coatFibrin Tissue AdhesiveBlood cellTransforming Growth Factor beta1Blood Transfusion AutologousLeukocyte CountThrombinTransforming Growth Factor betaWhite blood cellmedicineLeukocytesHumansPlateletPlatelet activationWhole bloodPeroxidasePlatelet-Derived Growth FactorWound HealingChromatographybiologyChemistryHematologyPlatelet Activationmedicine.anatomical_structureBiochemistryMyeloperoxidasebiology.proteinBlood Component RemovalGelsmedicine.drugTransfusion medicine (Oxford, England)
researchProduct

Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count.

2002

Abstract Introduction: Platelet-rich plasma contains autologous thrombocyte growth factors and might be promising for acceleration of dentoalveolar bone regeneration. In this study, it was analysed for platelet counts and growth factor concentrations. Material and method: Platelet-rich plasma was isolated by discontinuous cell separation from 158 healthy men and 55 women aged 17–62 years. One hundred and fifteen specimens (stratified for age and gender of the donor) were analysed for growth factor concentrations and platelet count. Results: The platelet count in platelet-rich plasma (1,407,640±320,100/μl) was 5 times higher than in donor blood (266,040±60,530/μl). Platelet-derived growth fa…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorAdolescentmedicine.medical_treatmentBecaplerminPlateletpheresisBlood DonorsEnzyme-Linked Immunosorbent AssayTransforming Growth Factor beta1chemistry.chemical_compoundTransforming Growth Factor beta2Sex FactorsTransforming Growth Factor betaInternal medicineMedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesPlatelet-Derived Growth Factorbiologybusiness.industryPlatelet CountGrowth factorPlateletpheresisAge FactorsProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyOtorhinolaryngologychemistryPlatelet-rich plasmabiology.proteinSurgeryFemaleOral SurgerybusinessGelsPlatelet-derived growth factor receptorTransforming growth factorJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Quantification of thrombocyte growth factors in platelet concentrates produced by discontinuous cell separation.

2002

Platelet concentrates (PC) are increasingly used to increase bone regeneration in pre-prosthetic surgery. Although it is generally appreciated that certain growth factors (PDGF, TGF, EGF, and ECGF) are present in thrombocyte preparations, relatively little is known about these components in quantitative terms. The study reported here analysed the amounts of growth factors in PC produced under standard conditions from healthy volunteers. All the blood samples (237 in total) were analysed using Quantikine ELISA kits (R and D). The mean +/- SD platelet count in whole blood from these donors was 262,000+/-58,000/microl, while in PC produced by discontinuous cell separation it was 1.419,000+/-33…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorTime Factorsmedicine.medical_treatmentClinical BiochemistryBecaplerminEnzyme-Linked Immunosorbent AssayCell SeparationTransforming Growth Factor beta1chemistry.chemical_compoundInsulin-like growth factorTransforming Growth Factor beta2EndocrinologySex FactorsTransforming Growth Factor betaInternal medicinemedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesWhole bloodAgedPlatelet-Derived Growth FactorChromatographybiologyChemistryGrowth factorCell BiologyProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyPlatelet-rich plasmabiology.proteinFemalePlatelet-derived growth factor receptorGrowth factors (Chur, Switzerland)
researchProduct

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

2012

Background & Aims Microparticles released into the bloodstream upon activation or apoptosis of CD4+ and CD8+ T cells correlate with inflammation as determined by histologic analysis in patients with chronic hepatitis C (CHC). Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver. Methods We compared profiles of circulating microparticles from patients with NAFL and NASH (n = 67) to those of CHC (n = 42), with healthy individuals (controls) using flow cytometry; the profiles were correlated with inflammation grade and fibrosis stage based on histologic an…

AdultCD4-Positive T-LymphocytesLiver CirrhosisMaleLymphocyteBiologyCD8-Positive T-LymphocytesChronic liver diseaseSeverity of Illness IndexArticleCell-Derived MicroparticlesDiagnosis DifferentialImmune systemFibrosisCell-Derived MicroparticlesNon-alcoholic Fatty Liver DiseasemedicineHumansAgedAged 80 and overInflammationHepatologyFatty liverBiopsy NeedleGastroenterologyAlanine TransaminaseHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFlow CytometryFatty Livermedicine.anatomical_structureAlanine transaminaseLiverROC CurveCase-Control StudiesImmunologybiology.proteinLinear ModelsFemaleBiomarkersGastroenterology
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct

Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications

2020

Heterozygous activating variants in platelet-derived growth factor, beta (PDGFRB) are associated with phenotypes including Kosaki overgrowth syndrome (KOGS), Penttinen syndrome and infantile myofibromatosis (IM). Here, we present three new cases of KOGS, including a patient with a novel de novo variant c.1477A > T p.(Ser493Cys), and the oldest known individual age 53 years. The KOGS phenotype includes characteristic facial features, tall stature, scoliosis, hyperelastic thin skin, lipodystrophy, variable intellectual and neurological deterioration, and abnormalities on brain imaging. Long-term outcome is unknown. Our cases confirm the phenotypic spectrum includes progressive flexion contrac…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyInfantile myofibromatosisPDGFRBScoliosis030105 genetics & heredityCraniosynostosisReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesCamptodactylyGeneticsmedicineHumansJoint dislocationStrokeGrowth DisordersGenetics (clinical)business.industryGenetic VariationMiddle Agedmedicine.diseaseCerebrovascular DisordersPhenotype030104 developmental biologymedicine.symptomLipodystrophybusinessClinical Genetics
researchProduct

Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis.

2001

Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EPX) are cytotoxic molecules involved in helminth infections and allergic reactions. Hitherto most clinical chemical studies have been concerned with the analysis of serum ECP in allergic diseases. The aim of this study was to examine whether serum as well as urine levels of these proteins are useful clinical chemical parameters in helminthiases and allergic diseases such as atopic dermatitis. Comparing these diseases under the same methodological conditions, levels of ECP and EPX were generally higher in helminthiases than in atopic dermatitis and non-helminth, non-allergic diseases. The highest levels of both proteins oc…

AdultMaleAllergyAdolescentHelminthiasisHelminthiasisEosinophil-derived neurotoxinSchistosomiasisEosinophil-Derived NeurotoxinBiologyDermatitis AtopicAtopyRibonucleasesPredictive Value of Testsparasitic diseasesmedicineEosinophiliaHumansEosinophil cationic proteinPublic Health Environmental and Occupational HealthProteinsAtopic dermatitisBlood ProteinsEosinophil Granule ProteinsMiddle Agedmedicine.diseaseInfectious DiseasesCase-Control StudiesImmunologyParasitologyFemalemedicine.symptomTropical medicineinternational health : TMIH
researchProduct

Clinical staging and serum cytokines in bipolar patients during euthymia

2017

Aims: Changes in serum cytokines and altered neutrophin concentration have been associated with bipolar disorder (BD). Our aim here was to analyze peripheral blood biomarkers according to the clinical stages of BD. Method: Euthymic BD-I patients were grouped according to their level of functioning in early-stage (n = 25) and late-stage (n = 23), and compared to healthy siblings (n = 23) and genetically unrelated healthy controls (n = 21). Neurotrophin (neurotrophin-3 and BDNF) concentration and biomarkers of inflammation, including cytokines (IL-6, IL-10 and TNF-alpha), leukocytes count and acute phase proteins, were measured. Results: IL-10 concentration was significantly increased in earl…

AdultMaleBipolar DisorderBipolar disorderInflammationNeurotrophinsYoung Adult03 medical and health sciences0302 clinical medicineNeurotrophin 3medicineLeukocytesHumansNerve Growth FactorsBipolar disorderBiological PsychiatryPharmacologyInflammationbiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryBrain-Derived Neurotrophic FactorSiblingsAcute-phase proteinMiddle Agedmedicine.diseaseBlood Cell CountInterleukin-10030227 psychiatryPeripheralAffectSerum cytokineClinical stagingCase-Control StudiesImmunologybiology.proteinBiomarker (medicine)CytokinesFemaleTumor necrosis factor alphamedicine.symptombusinessBiomarkers030217 neurology & neurosurgeryAcute-Phase ProteinsNeurotrophin
researchProduct

D2-40 negative pyogenic granuloma-like Kaposi's sarcoma: Diagnostic features and histogenetic hypothesis of an uncommon skin tumor in HIV-negative pa…

2015

Locate full-text(opens in a new window)|View at Publisher| Export | Download | Add to List | More... Pathology Research and Practice Volume 211, Issue 7, July 01, 2015, Pages 528-532 D2-40 negative pyogenic granuloma-like Kaposi's sarcoma: Diagnostic features and histogenetic hypothesis of an uncommon skin tumor in HIV-negative patients (Article) Cabibi, D.a, Giannone, A.G.a , Guarnotta, C.a, Schillaci, O.b, Franco, V.a a Department of Sciences for Promotion of Health and Mother and Child Care, University of Palermo, Palermo, Italy b Servizio di Anatomia Patologica, Dipartimento Oncologico di III livello, La Maddalena Casa di Cura di Alta Specialità, Palermo, Italy View references (20) Abst…

AdultMaleCD31Pathologymedicine.medical_specialtySkin NeoplasmsCD34Pyogenic granuloma-like Kaposi's sarcomaSettore MED/08 - Anatomia PatologicaVascular tumorPathology and Forensic MedicineD2-40Antibodies Monoclonal Murine-DerivedBiomarkers TumormedicineHHV8HumansGranuloma PyogenicSarcoma KaposiKaposi's sarcomaSkinRetrospective StudiesPodoplaninPyogenic granulomabusiness.industryKaposi's sarcomaCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryPyogenic granulomaLymphatic systemHerpesvirus 8 HumanFemaleSarcomaDifferential diagnosisbusinessImmunostainingPathology - Research and Practice
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct